Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentagestrone SCHEMBL21405771 | 0.98 | SHBG (0.51) | SHBGLMNACYP2C19MEN1NR3C1 | |
| SCHEMBL11208571 | 0.88 | LMNA (0.56) | SHBGLMNACYP2C19MEN1NR3C1 | |
| Penmesterol SCHEMBL547668 | 0.87 | SHBG (0.48) | SHBGLMNACYP2C19NR3C1MAPT | |
| SCHEMBL21405769 | 0.86 | PGR (0.52) | SHBGLMNACYP2C19MEN1NR3C1 | |
| SCHEMBL11517418 | 0.82 | SHBG (0.59) | SHBGLMNACYP2C19MEN1NR3C1 | |
| Quingestrone SCHEMBL145789 | 0.80 | SRD5A2 (0.58) | SHBGLMNACYP2C19MEN1NR3C1 | |
| SCHEMBL24358655 | 0.79 | SHBG (0.53) | SHBGLMNACYP2C19MEN1NR3C1 | |
| SCHEMBL9195965 | 0.79 | SHBG (0.53) | SHBGLMNACYP2C19MEN1NR3C1 | |
| SCHEMBL24358654 | 0.79 | SHBG (0.53) | SHBGLMNACYP2C19MEN1NR3C1 | |
| SCHEMBL11514918 | 0.77 | SHBG (0.60) | SHBGLMNACYP2C19MEN1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-101883556-B | Transdermal delivery system for hormones and steroids | ACRUX DDS PTY LTD | 2013-05-29 | — | — | CN | claimed |
| US-8110565-B2 | Of the ACE inhibitor ramipril; controlling the melting point by mixing with the free acid with the ramipril ethyl or methyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release | NOVEN PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| EP-1406633-B1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMA (US) | 2011-10-05 | — | — | EP | claimed |
| US-20110195114-A1 | TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS | ANTARES PHARMA, IPL, AG | 2011-08-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-7456159-B2 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20030232073-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | claimed |
| US-20030152614-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | claimed |
| US-20030152615-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | claimed |
| US-20030152613-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | claimed |
| WO-2002102390-A1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMACEUTICALS, INC. (US) | 2002-12-27 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| US-4016270-A | Method for treating dysmenorrhea with a uterine therapeutic system | ALZA CORPORATION (US) | 1977-04-05 | — | — | US | claimed |